DrugPatentWatch Database Preview

Details for Patent: 7,229,630

« Back to Dashboard

Which drugs does patent 7,229,630 protect, and when does it expire?

Patent 7,229,630 protects ORAVERSE and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 7,229,630

Title:	Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:	The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s):	Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee:	Novalar Pharmaceuticals, Inc. (DE)
Application Number:	10/465,810
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,229,630
Patent Claim Types: see list of patent claims	Formulation; Compound; Use; Dosage form; Composition; Device;

Drugs Protected by US Patent 7,229,630

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes			Y

International Family Members for US Patent 7,229,630

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003247568
Brazil	0311965
Brazil	PI0311965
Canada	2489526
China	100391460
China	1688312